Perrigo Co. PLC's top executives are asserting they are investing in the company’s Rx generic specialty topicals business for the long-term, rather than preparing it for divestment, as some analysts and board members prefer.
Discussion of the fate of the Rx business arose again on May 31 as the company completed its delayed 2017...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
